Auris Medical Holding Ltd (NASDAQ:EARS) Sees Significant Drop in Short Interest

Auris Medical Holding Ltd (NASDAQ:EARS) was the target of a large drop in short interest in September. As of September 30th, there was short interest totalling 79,500 shares, a drop of 48.7% from the August 30th total of 154,900 shares. Currently, 5.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 98,100 shares, the days-to-cover ratio is currently 0.8 days.

EARS traded down $0.41 during trading on Friday, reaching $2.19. 838,285 shares of the company traded hands, compared to its average volume of 130,249. Auris Medical has a 12-month low of $2.12 and a 12-month high of $39.40. The firm has a fifty day simple moving average of $2.78 and a 200 day simple moving average of $2.43. The company has a market cap of $4.80 million, a P/E ratio of -0.15 and a beta of -0.48.

A number of equities research analysts have issued reports on EARS shares. Zacks Investment Research lowered shares of Auris Medical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 22nd. ValuEngine raised shares of Auris Medical from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.

A hedge fund recently bought a new stake in Auris Medical stock. Jane Street Group LLC acquired a new stake in shares of Auris Medical Holding Ltd (NASDAQ:EARS) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 10,934 shares of the biotechnology company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.58% of Auris Medical at the end of the most recent reporting period. 10.25% of the stock is currently owned by institutional investors and hedge funds.

About Auris Medical

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Read More: What causes a stock to be most active?

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.